OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Risvutatug Rezetecan (Ris-Rez) Versus Gemcitabine and Docetaxel (GD) in Heavily Pretreated Patients With Relapsed or Refractory (R/R) Osteosarcoma: Primary Results From the Phase 3 ARTEMIS-011 Study

🦴 Phase 3 (n=122, China): B7-H3-directed ADC risvutatug rezetecan vs gemcitabine + docetaxel in R/R osteosarcoma after ≥2 prior lines; 25% adolescents. Primary endpoint: PFS by BICR.
➡️ Median PFS 5.5 vs 1.4 mo; HR 0.33; p<0.0001
➡️ OS immature; HR 0.51
➡️ Grade ≥3 TEAEs 92.5% vs 83.3%; treatment-related SAEs 63.8% vs 28.6%
✅ Significant PFS improvement with a favorable OS trend and manageable safety, highlighting potential as a new treatment standard for R/R osteosarcoma.
🎙️ Lu Xie

(4Sight Made from Abstracts publicly available at the ESMO website)